Abuse-deterrent extended-release oxycodone and risk of opioid-related harm.
Abuse-deterrent extended-release oxycodone and risk of opioid-related harm.
复制标题
DOI：
10.1111/add.15392
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Fazel S
中科院分区：
文献类型：
--
作者：
Paljarvi T;Strang J;Quinn PD;Luciano S;Fazel S
建立并量化防滥用制剂 (ADF) 羟考酮与阿片类药物相关危害的 1 年风险之间的关联。 2014 年至 2018 年电子病历倾向评分匹配队列研究，患者在指数医疗就诊后随访 1 年。来自 56 个美国医疗机构的超过 7000 万患者。首次就诊时年龄为 18 – 64 岁，有任何口服阿片类镇痛药指征，过去 12 个月没有口服羟考酮使用史或物质使用障碍，并且在 1 年随访结束时仍存活的患者（新的处方口服 ADF 羟考酮，n= 45,045；新的非 ADF 羟考酮阿片制剂， n=1,377,359）。国际疾病分类临床修改诊断在首次就诊后 1 年内诊断出任何阿片类药物相关疾病或非致命性阿片类药物中毒。具有 95% 置信区间 (95%CI) 的合并比值比 (OR)。经过倾向评分匹配后，纳入了 89,802 名平均年龄为 44 (SD:11) 岁的患者（62% 为女性，68% 为白人）。在 1 年随访期间，ADF 羟考酮队列中有 1,445 例诊断为阿片类药物使用障碍或阿片类药物中毒（34.8/1,000 人年），非 ADF 羟考酮队列中有 765 例诊断为阿片类药物使用障碍或阿片类药物中毒（18.2/1,000 人年）。与非 ADF 羟考酮阿片类药物队列相比，ADF 羟考酮队列中阿片类药物相关不良后果的几率增加，包括阿片类药物使用障碍 (OR:2.02; 95%CI:1.83, 2.23) 和阿片类药物中毒 (OR:1.64 95%CI:1.35, 1.99)。服用新的防滥用制剂羟考酮处方的患者可能面临阿片类药物相关伤害的风险增加。
To establish and quantify the association between abuse-deterrent formulation (ADF) oxycodone and 1-year risk of opioid-related harm. Propensity score-matched cohort study of electronic medical records for years 2014 – 2018, with patients followed up for 1 year after their index healthcare visit. Over 70 million patients from 56 US healthcare organizations. Patients aged 18 – 64 years at index healthcare visit with any indication for an oral opioid analgesic, with no past 12-month history of oral oxycodone use or substance use disorder, and who were alive at the end of the 1-year follow-up (new episode of prescription oral ADF oxycodone, n= 45,045; new episode of non-ADF oxycodone opioid preparation, n=1,377,359). International Classification of Diseases Clinical Modification diagnoses of any opioid-related disorder or non-fatal opioid poisoning within 1 year of the index healthcare visit. Pooled odds ratios (OR) with 95% confidence intervals (95%CI). After propensity score matching, 89,802 patients with a mean age of 44 (SD:11) years (62% women, 68% white) were included. During 1-year follow-up, 1,445 diagnoses of opioid use disorder or opioid poisoning occurred in the ADF oxycodone cohort (34.8/1,000 person-years), and 765 occurred in the non-ADF oxycodone cohort (18.2/1,000 person-years). The odds of opioid-related adverse outcomes were increased in the ADF oxycodone cohort compared with non-ADF oxycodone opioid cohort, including for opioid use disorders (OR:2.02; 95%CI:1.83, 2.23) and opioid poisoning (OR:1.64 95%CI:1.35, 1.99). Patients with a new prescription of abuse-deterrent formulation oxycodone may be at increased risk of opioid-related harm.
登录
查看更多内容
影响因子：
6.7
作者：
Coplan PM;Chilcoat HD;Butler SF;Sellers EM;Kadakia A;Harikrishnan V;Haddox JD;Dart RC
通讯作者：
Dart RC
影响因子：
7.4
作者：
Cicero, Theodore J.;Ellis, Matthew S.;Kasper, Zachary A.
通讯作者：
Kasper, Zachary A.
影响因子：
5.5
作者：
Abbasi, Ali B.;Salisbury-Afshar, Elizabeth;Pho, Mai T.
通讯作者：
Pho, Mai T.
CDC规定慢性疼痛的阿片类药物的指南 - 美国，2016年。
DOI：
10.1001/jama.2016.1464
发表时间：
2016-04-19
期刊：
JAMA
影响因子：
--
作者：
Dowell D;Haegerich TM;Chou R
通讯作者：
Chou R
影响因子：
168.9
作者：
Degenhardt, Louisa;Grebely, Jason;Larney, Sarah
通讯作者：
Larney, Sarah